IART Integra LifeSciences Holdings Corporation

Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO

Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO

PRINCETON, N.J., Aug. 16, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:IART), a leading global medical technology company, today announced that Dr. Richard Caruso, founder and former chairman and CEO of Integra LifeSciences passed away over the past weekend.

“Dr. Richard Caruso made an impact on not only the medical technology industry, but more importantly, on the countless lives around the world who have benefited from the products and technologies that Integra LifeSciences has today,” said Stuart Essig, chairman of the board at Integra LifeSciences. “His vision, transformative ideas and entrepreneurial spirit have revolutionized the way surgeons treat their patients in the field of regenerative medicine.”

Dr. Caruso founded Integra LifeSciences in 1989 with a vision that the human body could be enabled to regenerate many of its own damaged or diseased tissues, paving the way for a new discipline back then known as regenerative medicine. Through his vision, Integra became the first company to develop and bring to market a tissue regeneration product, Integra® Dermal Regeneration Template, which was approved by the FDA in 1996 as a skin replacement system with a claim for regeneration of dermal tissue for the treatment of life-threatening burns and repair of scar contractures. That technology led to the development of DuraGen® Dural Graft Matrix, for repair of the dura mater, the protective covering of the brain after cranial and spine surgery, and NeuraGen® Nerve Guide, which creates a conduit for axonal growth across a severed nerve.

Dr. Caruso served as Integra's chairman from 1992 until 2011, and served as CEO from 1992 to 1997. In addition, he served on the Board of Susquehanna University and the Baum School of Art. Dr. Caruso received his B.S. degree from Susquehanna University, an M.S.B.A. degree from Bucknell University, and a Ph.D. degree from the London School of Economics, University of London. He was also the founder and director of The Uncommon Individual Foundation, a non-profit foundation that encourages individuals to form and follow their dreams of personal success and become the entrepreneurs of their personal lives.

About Integra LifeSciences

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Aurora®, Bactiseal®, BioD, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®, Gentrix®, ICP Express®, Integra®, Licox® , MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®, NeuraGen® , NeuraWrap , PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®. For the latest news and information about Integra and its products, please visit .

Investor Relations Contact:

Chris Ward

(609) 772-7736

Media Contact:

Laurene Isip

(609) 208-8121

A photo accompanying this announcement is available at .



EN
16/08/2022

Underlying

Reports on Integra LifeSciences Holdings Corporation

 PRESS RELEASE

Integra LifeSciences Leadership to Present at the Citi 2025 Global Hea...

Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025 at 10:30 a.m ET A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under . About Integra LifeSciencesAt Integra LifeSc...

 PRESS RELEASE

Integra LifeSciences Welcomes Policy Advancements Supporting Medicare ...

Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access Company to advance care through broader access to breadth of skin substitutes across four unique technology platforms PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, commends the Centers for Medicare & Medicaid Services (CMS) on its Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules. All Integra dermal regenerative templates, decellularized dermal scaffolds and amniotic tissue membranes, ...

 PRESS RELEASE

Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA...

Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance for use of its for cardiac surgeries. The recent clearance for specific cardiac indications encompasses the debridement of unwanted tissue in cardiac surgeries, including valve replacement and repair. In addition to cardiac surgery, the CUSA Clarity Ultrasonic Surgical Aspirator System is ind...

 PRESS RELEASE

Integra LifeSciences Reports Third Quarter 2025 Financial Results

Integra LifeSciences Reports Third Quarter 2025 Financial Results PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2025. Third Quarter 2025 Highlights Third quarter revenues of $402.1 million increased 5.6% on a reported basis and 5.0% on an organic basis compared to the prior year. Third quarter GAAP earnings per diluted share of $(0.07), compared to $(0.14) in the prior year. Adjusted earnings per diluted s...

 PRESS RELEASE

Integra LifeSciences to Host Third Quarter 2025 Financial Results Conf...

Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025 PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: IART), a leading global medical technology company, will release third quarter 2025 financial results on Thursday, October 30, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register  to receive dia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch